Physician profile
Adolfo E Diaz
NPI 1730463324
$462,725.81
in general payments reported to CMS, 2019-2025
16 companies · $115K in 2025
The $115K reported for 2025 was more than what 99% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29K · 2020: $11K · 2021: $19K · 2022: $65K · 2023: $131K · 2024: $93K · 2025: $115K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $249K · Travel and Lodging: $55K · Honoraria: $27K · Food and Beverage: $6,689 · Consulting Fee: $1,740 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $249,168.75 |
| Travel and Lodging | $54,812.38 |
| Honoraria | $26,970.00 |
| Food and Beverage | $6,689.24 |
| Consulting Fee | $1,740.00 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $151,399.79 | 2021-2025 | Monjuvi, Monjuvi |
| Adc Therapeutics America, INC. | $111,650.69 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $65,569.33 | 2022-2025 | Calquence |
| Lilly USA, LLC | $50,962.72 | 2022-2023 | Jaypirca, Verzenio |
| Genentech USA, INC. | $39,418.72 | 2022-2025 | Polivy, Lunsumio, Columvi |
| Seagen INC. | $22,960.25 | 2019-2020 | |
| Verastem, INC. | $11,590.77 | 2019-2020 | |
| Abbvie INC. | $4,712.74 | 2019 | |
| Epizyme, INC. | $2,250.00 | 2021 | |
| Morphosys, US INC. | $1,740.00 | 2024 | Monjuvi |
| Viiv Healthcare Company | $249.98 | 2023-2025 | Dovato |
| Novo Nordisk INC | $117.41 | 2023 | |
| Pfizer INC. | $54.13 | 2025 | |
| Regeneron Pharmaceuticals, INC. | $36.08 | 2024 | |
| Genmab U.S., INC. | $13.20 | 2023 | Epkinly |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adolfo Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.